APA (7th ed.) Citation

Patnaik, A., Weiss, G. J., Rasco, D. W., Blaydorn, L., Mirabella, A., Beeram, M., . . . Sachdev, J. C. (2022). Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: A dose–escalation phase 1 trial. Cancer chemotherapy and pharmacology, 89(1), 93-103. https://doi.org/10.1007/s00280-021-04358-3

Chicago Style (17th ed.) Citation

Patnaik, Amita, et al. "Safety, Antitumor Activity, and Pharmacokinetics of Dostarlimab, an Anti-PD-1, in Patients with Advanced Solid Tumors: A Dose–escalation Phase 1 Trial." Cancer Chemotherapy and Pharmacology 89, no. 1 (2022): 93-103. https://doi.org/10.1007/s00280-021-04358-3.

MLA (9th ed.) Citation

Patnaik, Amita, et al. "Safety, Antitumor Activity, and Pharmacokinetics of Dostarlimab, an Anti-PD-1, in Patients with Advanced Solid Tumors: A Dose–escalation Phase 1 Trial." Cancer Chemotherapy and Pharmacology, vol. 89, no. 1, 2022, pp. 93-103, https://doi.org/10.1007/s00280-021-04358-3.